bloodjourГематология и трансфузиологияRussian journal of hematology and transfusiology0234-57302411-3042ООО Издательский дом «Практика»10.35754/0234-5730-2019-64-3-353-361bloodjour-153Research ArticleКЛИНИЧЕСКИЕ НАБЛЮДЕНИЯCASE REPORTSТЕРАПИЯ РЕЗИСТЕНТНЫХ ФОРМ ПОДКОЖНОЙ ПАННИКУЛИТОПОДОБНОЙ Т-КЛЕТОЧНОЙ ЛИМФОМЫTHERAPY OF THE RESISTANT FORMS OF SUBCUTANEOUS PANNICULITIS-LIKE T-CELL LYMPHOMAhttps://orcid.org/0000-0002-3967-9183ГоренковаЛ. Г.GorenkovaL. G.

кандидат медицинских наук, научный сотрудник отделения интенсивной высокодозной химиотерапии гемобластозов с круглосуточным стационаром,

125167, г. Москва, Новый Зыковский проезд, 4

Cand. Sci. (Med.), Researcher, Department of Intensive High-Dose Chemotherapy for Hemoblastoses,

125167, Moscow, Novyy Zykovskiy proezd, 4

l.aitova@mail.ruhttps://orcid.org/0000-0002-7721-2074КравченкоС. К.KravchenkoS. K.

кандидат медицинских наук, доцент, заведующий отделением интенсивной высокодозной химиотерапии гемобластозов с круглосуточным стационаром,

125167, г. Москва, Новый Зыковский проезд, 4

Cand. Sci. (Med.), Head of the Department of Intensive High-Dose Chemotherapy for Hemoblastoses, 

125167, Moscow, Novyy Zykovskiy proezd, 4

kravchenko.s@blood.ruhttps://orcid.org/0000-0002-4937-018XСилаевМ. А.SilaevM. A.

кандидат медицинских наук, врач-хирург научно-клинического отделения гематологической хирургии,

125167, г. Москва, Новый Зыковский проезд, 4

Cand. Sci. (Med.), Surgeon, Scientific and Clinical Department of Hematological Surgery, 

125167, Moscow, Novyy Zykovskiy proezd, 4

silaev.m@blood.ruhttps://orcid.org/0000-0003-2424-9524РыжиковаН. В.RyzhikovaN. V.

научный сотрудник лаборатории молекулярной гематологии,

125167, г. Москва, Новый Зыковский проезд, 4

Researcher, Laboratory of Molecular Haematology,

125167, Moscow, Novyy Zykovskiy proezd, 4

ryzhykova.n@blood.ruФГБУ «Национальный медицинский исследовательский центр гематологии» Министерства здравоохранения Российской ФедерацииРоссияNational Research Center for HematologyRussian Federation201909112019643353361Copyright © Горенкова Л.Г., Кравченко С.К., Силаев М.А., Рыжикова Н.В., 20192019Горенкова Л.Г., Кравченко С.К., Силаев М.А., Рыжикова Н.В.Gorenkova L.G., Kravchenko S.K., Silaev M.A., Ryzhikova N.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.htjournal.ru/jour/article/view/153Введение

Введение. Подкожная панникулитоподобная Т-клеточная лимфома (ППТКЛ) относится к редкой группе кожных лимфопролиферативных заболеваний с клиническими проявлениями, напоминающими панникулит, α/β-цитотоксическим иммунофенотипом опухолевых клеток и разнонаправленным течением: от индолентных до агрессивных форм.

Цель работы — описать больных ППТКЛ с агрессивным клиническим течением заболевания и рефрактерностью к нескольким линиям химиотерапии.

Результаты

Результаты. Представлены два клинических наблюдения больных с генерализованным характером поражения и наличием факторов неблагоприятного прогноза, у которых достигнуты полные продолжительные ремиссии заболевания в результате применения курсов химиотерапии с включением гемцитабина.

Заключение

Заключение: несмотря на то, что у обоих больных ППТКЛ наблюдалась рефрактерность как минимум к трем видам лечения, использование гемцитабина позволило достигнуть длительных полных ремиссий заболевания. 

Introduction

Introduction. Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) belongs to a rare group of skin lymphoproliferative disorders, which is characterised by panniculitis-like clinical manifestations, the α/β cytotoxic immunophenotype of tumour cells, as well as a multidirectional course from indolent to aggressive forms.

Aim

Aim. To examine patients with SPTCL having an aggressive clinical course and characterised by refractoriness to several lines of chemotherapy.

Results

Results. We present two case reports of patients with a generalised lesions and unfavourable prognostic factors, who achieved complete long-term remission of the disease as a result of gemcitabine chemotherapy.

Conclusion

Conclusion. Despite the fact that both observed SPTCL patients demonstrated refractoriness to at least three types of treatment, the use of gemcitabine allowed long-term complete remissions of the disease to be achieved. 

подкожная панникулитоподобная Т-клеточная лимфомалимфома кожиремиссия заболеванияволчаночный панникулитгемцитабинsubcutaneous panniculitis-like T-cell lymphomaskin lymphomadisease remissionlupus panniculitisgemcitabineReferencesGonzalez C.L., Medeiros L.J., Braziiel R.M., Jaffe E.S. T-cell lymphoma involving subcutaneous tissue: a clinicopathologic entity commonly associated with hemophagocytic syndrome. Am J Surg Pathol. 1991; 15(1): 17–27.Gonzalez C.L., Medeiros L.J., Braziiel R.M., Jaffe E.S. T-cell lymphoma involving subcutaneous tissue: a clinicopathologic entity commonly associated with hemophagocytic syndrome. Am J Surg Pathol. 1991; 15(1): 17–27.Hoque S.R., Child F.J., Whittaker S.J. et al. Subcutаneous panniculitis-like T-cell lymphoma: a clinicopathological, immunophenotypic and molecular analysis of six patients. Br J Dermatol. 2003; 148 (3): 516–25.Hoque S.R., Child F.J., Whittaker S.J. et al. Subcutаneous panniculitis-like T-cell lymphoma: a clinicopathological, immunophenotypic and molecular analysis of six patients. Br J Dermatol. 2003;148 (3): 516–25.Lozzi G.P., Massone C., Citarella L. et al. Rimming of adipocytes by neoplastic lymphocytes:a histopathologic feature not restricted to subcutaneous T-cell lymphoma. Am J Dermatopathol. 2006; 28: 9–12.Lozzi G.P., Massone C., Citarella L. et al. Rimming of adipocytes by neoplastic lymphocytes:a histopathologic feature not restricted to subcutaneous T-cell lymphoma. Am J Dermatopathol. 2006; 28: 9–12.Willemze R., Cerroni L., Kempf W. et al. The 2018 update of the WHO-EORTC classifi cation for primary cutaneous lymphomas. Blood. 2019; 133 (16): 1703– 14. DOI: 10.1182/blood-2018-11-881268Willemze R., Cerroni L., Kempf W. et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019; 133 (16): 1703– 14. DOI: 10.1182/blood-2018-11-881268Swerdlow S.H., Campo E., Pileri S.A. et al. The 2016 revision of the World Health Organization classifi cation of lymphoid neoplasms. Blood. 2016; 127: 2375–90.Swerdlow S.H., Campo E., Pileri S.A. et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127: 2375–2390.Lopez-Lerma I., Penate Y., Gallardo F. Subcutaneous panniculitis-like T-cell lymphoma: clinical features, therapeutic approach, and outcome in a case series of 16 patients. J Am Acad Dermatol. 2018; 79(5): 892–8.Lopez-Lerma I., Penate Y., Gallardo F. Subcutaneous panniculitis-like T-cell lymphoma: clinical features, therapeutic approach, and outcome in a case series of 16 patients. J Am Acad Dermatol. 2018; 79(5): 892–8.Rutnin S., Porntharukcharoen S., Boonsakan P. Clinicopathologic, immunophenotypic, and molecular analysis of subcutaneous panniculitis-like T-cell lymphoma: A retrospective study in a tertiary care center. J Cutan Pathol. 2019; 46 (1): 44–51.Rutnin S., Porntharukcharoen S., Boonsakan P. Clinicopathologic, immunophenotypic, and molecular analysis of subcutaneous panniculitis-like T-cell lymphoma: A retrospective study in a tertiary care center. J Cutan Pathol. 2019; 46 (1): 44–51.Willemze R., Jansen P.M., Cerroni L. et al. Subcutaneous panniculitis-like T-cell lymphoma: defi nition, classifi cation, and prognostic factors: an EORTC Cutaneous Lymphoma Group study of 83 cases. Blood. 2008; 111(2): 838–45.Willemze R., Jansen P.M., Cerroni L. et al. Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group study of 83 cases. Blood. 2008; 111(2): 838–45.Michonneau D., Petrella T., Ortonne N. et al. Subcutaneous panniculitis-like T-cell lymphoma: immunosuppressive drugs induce better response than polychemotherapy. Acta Derm Venereol. 2017; 97(3): 358–64.Michonneau D., Petrella T., Ortonne N. et al. Subcutaneous panniculitis-like T-cell lymphoma: immunosuppressive drugs induce better response than polychemotherapy. Acta Derm Venereol. 2017; 97(3): 358–64.Michot C., Costes V., Gerard-Dran D. et al. Subcutaneous panniculitis-like T-cell lymphoma in a patient receiving etanercept for rheumatoid arthritis. Br J Dermatol. 2009; 160: 889–90.Michot C., Costes V., Gerard-Dran D. et al. Subcutaneous panniculitis-like T-cell lymphoma in a patient receiving etanercept for rheumatoid arthritis. Br J Dermatol. 2009; 160: 889–90.Bregman S.G., Yeaney G.A.,Greig B.W. et al. Subcutaneous panniculitislike T-cell lymphoma in a cardiac allograft recipient. J Cutan Pathol. 2005; 32: 366–70.Bregman S.G., Yeaney G.A.,Greig B.W. et al. Subcutaneous panniculitislike T-cell lymphoma in a cardiac allograft recipient. J Cutan Pathol. 2005; 32: 366–70.Margo C.M., Wang X. CCL5 expression in panniculitic T-cell dyscrasias and its potential role in adipocyte tropism. Am J Dermatopathol. 2013; 35: 332–7.Margo C.M., Wang X. CCL5 expression in panniculitic T-cell dyscrasias and its potential role in adipocyte tropism. Am J Dermatopathol. 2013; 35: 332–7.Kong Y.Y., Dai B., Kong J.C. et al. Subcutaneous panniculitis-like T-cell lymphoma: a clinicopathologic, immunophenotypic and molecular study of 22 Asian cases according to WHO-EORTC classifi cation. Am J Surg Pathol. 2008; 32 (10): 1495–502.Kong Y.Y., Dai B., Kong J.C. et al. Subcutaneous panniculitis-like T-cell lymphoma: a clinicopathologic, immunophenotypic and molecular study of 22 Asian cases according to WHO-EORTC classification. Am J Surg Pathol. 2008; 32 (10): 1495–502.Ohtsuku M., Miura T., Yamamoto T. Clinical characteristics, differential diagnosis, and treatment outcome of subcutaneous panniculitis-like T-cell lymphoma: a literature review of published Japanese cases. Eur J Dermatol. 2017; 27(1): 34–41.Ohtsuku M., Miura T., Yamamoto T. Clinical characteristics, differential diagnosis, and treatment outcome of subcutaneous panniculitis-like T-cell lymphoma: a iterature review of published Japanese cases. Eur J Dermatol. 2017; 27(1): 34–41.Yi L., Qun S., Wenjie Z. et al. The presenting manifestations of subcutaneous panniculitis-like T-cell lymphoma and T-cell lymphoma and cutaneous γ/δ T-cell ymphoma may mimic those of rheumatic diseases: a report of 11 cases. Clin Rheumatol. 2013; 32: 1169–75.Yi L., Qun S., Wenjie Z. et al. The presenting manifestations of subcutaneous panniculitis-like T-cell lymphoma and T-cell lymphoma and cutaneous γ/δ T-cell lymphoma may mimic those of rheumatic diseases: a report of 11 cases. Clin Rheumatol. 2013; 32:1169–75.Willemze R. Cutaneous lymphomas with a panniculitic presentation. Seminars in Diagnostic Pathology. 2017; 34(1): 36–43. DOI: 10.1053/j.semdp.2016.11.009.Willemze R. Cutaneous lymphomas with a panniculitic presentation. Seminars in Diagnostic Pathology. 2017; 34(1): 36–43. DOI: 10.1053/j.semdp.2016.11.009.Lee D.W., Yang J.H., Lee S.M. et al. Subcutaneous panniculitis-like T-cell lymphoma: a clinical and pathologic study of 14 Korean patients. Ann Dermatol. 2011; 23(3): 329–37.Lee D.W., Yang J.H., Lee S.M. et al. Subcutaneous panniculitis-like T-cell lymphoma: a clinical and pathologic study of 14 Korean patients. Ann Dermatol. 2011; 23(3): 329–37.Sitthinamsuwan P, Pattanaprichakul P., Treetipsatit J. et al. Subcutaneous Panniculitis-Like T-Cell Lymphoma Versus Lupus Erythematosus Panniculitis: Distinction by Means of the Periadipocytic Cell Proliferation Index. Am J Dermatopathol. 2018; 40(8): 567–74.Sitthinamsuwan P, Pattanaprichakul P., Treetipsatit J. et al. Subcutaneous Panniculitis-Like T-Cell Lymphoma Versus Lupus Erythematosus Panniculitis: Distinction by Means of the Periadipocytic Cell Proliferation Index. Am J Dermatopathol. 2018; 40(8): 567–74.Pincus L.B., LeBoit P.E., McCalmont T.H. et al. Subcutaneous panniculitis-like T-cell lymphoma with overlapping clinicopathologic features of lupus erythematosus: coexistence of 2 entities. Am J Dermatopayhol. 2009; 31: 520–6.Pincus L.B., LeBoit P.E., McCalmont T.H. et al. Subcutaneous panniculitis-like T-cell lymphoma with overlapping clinicopathologic features of lupus erythematosus: coexistence of 2 entities. Am J Dermatopayhol. 2009; 31: 520–26.Massone C., Lozzi G.P., Egberts F. et al. The protean spectrum of non-Hodgkin lymphomas with prominent involvement of subcutaneous fat. J. Cutan. Pathol. 2006; 33: 418–25.Massone C., Lozzi G.P., Egberts F. et al. The protean spectrum of non-Hodgkin lymphomas with prominent involvement of subcutaneous fat. J. Cutan. Pathol. 2006; 33: 418–25.Mizutani S., Kuroda J., Shimura Y. et al. Cyclosporine A for chemotherapyresistant subcutaneous panniculitis-like T cell lymphoma with hemophagocytic syndrome. Acta Haematol. 2011; 126: 8–12.Mizutani S., Kuroda J., Shimura Y. et al. Cyclosporine A for chemotherapyresistant subcutaneous panniculitis-like T cell lymphoma with hemophagocytic syndrome. Acta Haematol. 2011; 126: 8–12.Jang M.S., Baek J.W., Kang D.Y. et al. Subcutaneous panniculitis-like T-cell lymphoma: successful treatment with systemic steroid alone. J. Dermatol. 2012; 39(1): 96–9.Jang M.S., Baek J.W., Kang D.Y. et al. Subcutaneous panniculitis-like T-cell lymphoma: successful treatment with systemic steroid alone. J. Dermatol. 2012; 39(1): 96–9.Briki H., Bouaziz J.D., Molinier-Frenkel V. et al. Subcutaneous panniculitis-like T-cell lymphoma: complete sustained remission with corticosteroids and methotrexate. Br J Dermatol. 2010; 163(5): 1136–8.Briki H., Bouaziz J.D., Molinier-Frenkel V. et al. Subcutaneous panniculitis-like T-cell lymphoma: complete sustained remission with corticosteroids and methotrexate. Br J Dermatol. 2010; 163(5): 1136–8.Go R.S., Wester S.M. Immunophenotypic and molecular features, clinical outcomes, treatments, and prognostic factors associated with subcutaneous panniculitis-like T-cell lymphoma: a systemic analysis of 156 patients reported in literature. Cancer. 2004; 101(6): 1404–13.Go R.S., Wester S.M. Immunophenotypic and molecular features, clinical outcomes, treatments, and prognostic factors associated with subcutaneous panniculitis-like T-cell lymphoma: a systemic analysis of 156 patients reported in literature. Cancer. 2004; 101(6): 1404–13.Mellgren K., Attarbaschi A., Abla O. et al. Non-anaplastic peripheral T-cell lymphoma in children and adolescents — an International review of 143 cases. Ann Hematol. 2016; 95(8): 1295–305.Mellgren K., Attarbaschi A., Abla O. et al. Non-anaplastic peripheral T-cell lymphoma in children and adolescents — an International review of 143 cases. Ann Hematol. 2016; 95(8): 1295–305.Cheson B.D. PET/CT in lymphoma: Current overview and future directions. Semin Nucl Med, 2018; 48(1): 76–81.Cheson B.D. PET/CT in lymphoma: Current overview and future directions. Semin Nucl Med, 2018; 48(1): 76–81.Ng M., Waters J., Cunningham D. et al. Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. Br J Cancer. 2005; 92(8): 1352–7.Ng M., Waters J., Cunningham D. et al. Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. Br J Cancer. 2005; 92(8): 1352–7.Yim K.L., Ashley S. Assessment of gemcitabine, cisplatin and methylprednisolone (GEM-P) combination treatment for non-Hodgkin T cell lymphoma. Med Oncol. 2012; 29(5): 3535–9.Yim K.L., Ashley S. Assessment of gemcitabine, cisplatin and methylprednisolone (GEM-P) combination treatment for non-Hodgkin T cell lymphoma. Med Oncol. 2012; 29(5): 3535–9.

The authors declare that there are no conflicts of interest present.